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| INTRODUC TI ON
Breast cancer has ranked the most common cancer and the leading cause of cancer death among females worldwide, which accounts for estimated 1 700 000 new cases and causes 520 000 deaths around the world according to 2015 global statistics. 1 In China, breast cancer occurs in 268 600 new cases and results in 69 500 deaths in females. 1, 2 With the development in medical technology, various treatment options have been applied in breast cancer patients (such as surgery, chemotherapy, endocrine therapy, as well as targeted therapies). 3, 4 Early breast cancer is considered potentially curable with these measurements, whereas the efficacy of current available treatments is still limited for the disease metastasis that is responsible for 90% of the deaths from breast cancer. [3] [4] [5] Thus, exploration of novel treatment target as well as convincing biomarker for prognosis is of great importance for management of breast cancer progression.
Integrins are a large family of heterodimeric cell surface receptors that regulated cell-cell and cell-extracellular matrix interactions. 6 Integrin α7 (ITGA7) is a gene localized on chromosome 12q13 and composed of at least 27 exons spanning a region of around 22.5 kb, which is the receptor for the extracellular matrix (ECM) protein laminin and forms heterodimer with integrin β1. 7 Recently, the functions of ITGA7 in cancers have attracted increasing attentions. Several previous studies have disclosed that ITGA7 is upregulated and correlates with adverse clinicopathological characteristics in some cancers (such as esophageal squamous cell carcinoma and clear cell renal cell carcinoma). 7, 8 Moreover, some in vitro experiments have disclosed that ITGA7 serves as a tumor oncogene in different cancer cells (such as glioblastoma and pancreatic carcinoma) through affecting cell proliferation and invasion. 8, 9 Considering these implications about the promotive effect of ITGA7 in different cancers, we speculated that ITGA7 also might contribute to the progression of breast cancer and might be a potential treatment target, while relevant evidence is still limited. Thus, we conducted this study to investigate the correlation of ITGA7 expression with clinical/pathological characteristics and overall survival (OS) in breast cancer patients and further explore its knockdown on inhibiting breast cancer cell activities in vitro. fering from other malignancies. The approval for this study was obtained from the Ethics Committee of GanSu Provincial Cancer Hospital, and verbal (with recording) or written informed consents were collected from included patients or their guardians.
| MATERIAL S AND ME THODS

| Patients
| Data collection
The screening and data retrieving were conducted in June 2018, and patients' clinical data including age, tumor size, T stage, N stage, M stage, tumor-node metastasis (TNM) stage, pathological grade, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor-2 (HER-2) status, as well as survival records were collected. The pathological grade was classi- 
| Sample collection and ITGA7 expression
All formalin-fixed, paraffin-embedded tumor tissues were collected from the Pathology Department after approval by the Hospital. Specimens were cut onto 5-µm slices, dried at 65℃ for 3 hours, deparaffinized in xylene (Catalog number: 95682; Sigma), followed by rehydration using gradient ethanol. Then, the slices were transparentized by polybutylene terephthalate and soaked in the solution of 1% bovine serum albumin (BSA) (Catalog number: A1933; Sigma) +0.1% Triton X-100 (Catalog number: T9284; Sigma) for 30 minutes. Next, slices were quenched with fresh 3% hydrogen peroxide (Catalog number: 323381; Sigma) to inhibit endogenous tissue peroxidase activity, and the antigen retrieval was performed using microwave. After blocked by 10% goat serum (Catalog number: 50062Z; Thermo), the slices were incubated with rabbit anti-ITGA7 antibody (Catalog number: ab203254; Abcam) at a dilution of 1:500 in buffer 4℃ overnight. Next day, slices were washed in buffer and then were incubated with Alexa Fluor ® 488 conjugate-labeled antibody against rabbit IgG (Catalog number: #4412; CST) at dilution of 1:500. After that, the slices were washed with phosphate buffer saline (PBS) and followed by 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) (Catalog number: D3571; Invitrogen) staining and then were covered with coverslips. All slices were evaluated by 50i Nikon microscope in dark, and ITGA7 expression was semi-quantitatively assessed by using the following intensity categories: 0, no staining; 1, weak but detectable staining; 2, moderate or distinct staining; and 3, intense staining. A histological score (HSCORE) was derived from the formula HSCORE = ΣPi(i + 1), where i represents the intensity scores, and Pi is the corresponding percentage of the cells. According to the HSCORE, ITGA7 high expression was defined as HSCORE > 0.7, and the ITGA7 low expression was defined as HSCORE ≤ 0.7. 10 Furthermore, RNA was extracted from the FFPE tissue and detected by real-time quantitative polymerase chain reaction (RT-qPCR). Sigma), and crystal violet (Catalog number: 46364; Sigma) according to the method described previously. 11
| ITGA7 knockdown in breast cancer cell line
| Detection of cell proliferation, cell apoptosis, and cell invasion
| Western blot
Western blot was performed as the following steps: 
| RT-qPCR
RT-PCR was performed as the following steps: (a) with TRIzol reagent (Catalog number: 15596018; Invitrogen), extraction of total RNA was performed; (b) the reverse transcription to cDNA was con- 
| Statistical analysis
| RE SULTS
| Study flow
Totally 395 breast cancer patients who underwent surgical resection were retrospectively screened in this study, while 181 of them were excluded, including 69 patients with no preserved tumor tissue, 45 patients with incomplete clinical data, 37 patients underwent neoadjuvant therapy, 21 patients with relapsed or secondary cancer, and nine patients with other malignancies (Figure 1 ). Subsequently, in the 214 patients eligible, 23 patients who were unable to acquire informed consents were excluded, and finally 191 patients were reviewed and analyzed in this study. 
| Baseline characteristics
| ITGA7 expression in breast cancer patients
Examples of tumor ITGA7 high expression and ITGA7 low expression are shown in Figure 2A . In totally 191 patients, 92 (48.2%) patients presented with ITGA7 high expression, and 99 (51.8%) patients presented with ITGA7 low expression ( Figure 2B ). 
| Correlation of ITGA7 expression with clinical characteristics in breast cancer patients
| Correlation of ITGA7 expression with OS in breast cancer patients
K-M curves displayed that ITGA7 protein high expression was associated with shorter OS (P < .001) ( Figure 3A) ; moreover, ITGA7 mRNA high expression was correlated with worse OS in breast cancer patients (P = .009) ( Figure 3B ).
| Analysis of factors affecting OS in breast cancer patients
Univariate Cox's regression displayed that ITGA7 high expression (P < .001) was associated with shorter OS, and larger tumor size (P < .001), higher T stage (P < .001), higher N stage (P < .001), higher TNM stage (P < .001), and higher pathological grade (P < .001) were also associated with worse OS in breast cancer patients ( whereas ER (positive vs negative) (P = .010) and PR (positive vs negative) (P = .022) were correlated with longer OS in breast cancer patients. Furthermore, the multivariate Cox's regression analysis revealed that ITGA7 high expression was an independent predictive factor for poorer OS (P = .006) in breast cancer patients, and higher pathological grade also independently predicted unfavorable OS (P = .001) in breast cancer patients.
| Effect of ITGA7 knockdown on cell proliferation, cell apoptosis, and cell invasion in MCF7 cells
In order to assess the effect of ITGA7 knockdown on cell functions in breast cancer cells, control shRNA and ITGA7 shRNA plasmids were constructed and transfected into MCF7 cells. After transfection at 24 hours, the expressions of ITGA7 mRNA (P < .01) and
ITGA protein were reduced in ITGA7 knockdown group compared to control group (Figure 4A cell differentiation, and cell metastasis in cancers. 12, 13 For instance, some studies disclose that ITGA7 knockdown inhibits Hsp27-mediated cell invasion in HCC cells and decreases S100P-mediated cell migration in lung cancer cells. 14, 15 Besides, a study shows that ITGA7
| D ISCUSS I ON
represses cell apoptosis as well as promotes chemoresistance via activating focal adhesion kinase (FAK)/Akt signaling, but enhances cell metastasis via inducing epithelial-mesenchymal transition (EMT) in OSCC cells. 7 Another study illustrates that ITGA7 knockdown might inhibit cell proliferation via decreasing phosphorylated AKT and p38 in glioblastoma cells. 8 These previous data reveal that ITGA7 may be involved in the initiation and progression of some cancers, and it is able to affect some vital biological functions (such as cell apoptosis, cell invasion, and chemotaxis) of cancer cells via regulating multiple pathways (such as FAK/Akt signaling and phosphatidylinositol 3-kinase (PI3K)/Akt pathway).
In a few observational studies, the role of aberrant ITGA7 expression in some cancers has been disclosed. 7, 8 For example, a study shows that ITGA7 overexpression correlates with increased disease grade in glioblastoma patients. 8 Another study displays that ITGA7 high expression is remarkably associated with poor differentiation and lymph node metastasis in esophageal squamous cell carcinoma patients. 7 These previous studies reveal that ITGA7 high expression correlates with aggravated disease progression in these cancer patients, while the correlation of ITGA7 with disease progression in breast cancer is still inconclusive. In this study, we enrolled 191 breast cancer patients to explore the correlation of ITGA7 with disease progression of breast cancer patients. We found that ITGA7 high expression was associated with raised T stage, increased TNM stage, and elevated pathological grade in breast cancer patients, which might due to the following reasons: (a) ITGA7 might increase cell proliferation via inactivating the phosphorylation of AKT and p38 and promote cell invasion through interacting with Hsp27 or S100P to facilitate tumor growth and tumor invasion; thus, it led to increased T stage as well as TNM stage; (b) ITGA7 drove cancer stem cell features through FAK/MAPK/ERK-mediated pathway, thereby enhanced abilities of self-renew and differentiation, which further led to increased pathological grade in breast cancer patients. 7 Furthermore, for the predictive value of ITGA7 on the treatment outcomes of cancer patients, ITGA7 high expression is 16, 17 Also, ITGA7 expression is negatively correlated with OS in both lowand high-grade glioma patients. 8 In conclusion, ITGA7 high expression correlates with increased T stage, TNM stage, and pathological grade as well as worse OS, and its knockdown enhances cell apoptosis but inhibits cell proliferation and invasion in breast cancer.
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F I G U R E 4 CCK-8, AV/PI, and Matrigel invasion assays. ITGA7 mRNA expression was decreased in ITGA7 knockdown group compared to control group (A). ITGA7 protein expression was lower in ITGA7 knockdown group compared to control group (B). Cell viability was reduced in ITGA7 knockdown group compared to control group at 48 h and 72 h (C). Cell apoptosis rate was increased in ITGA7 knockdown group compared to control group (D, E). Cell count using Matrigel invasion assay was reduced in ITGA7 knockdown group compared to control group (F, G). Comparison between two groups was determined by t test. P < .05 was considered significant. *P < .05; **P < .01; ***P < .001. CCK-8, Cell Counting Kit-8; AV/PI, Annexin V/ propidium iodide; ITGA7, integrin α7 O RCI D Chen Gao https://orcid.org/0000-0002-9262-080X
